Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer | Zendy

Zhihao Lü | Zendy; Jianling Zou | Zendy; Ying Hu | Zendy; Shuang Li | Zendy; Tao Zhou | Zendy; Jifang Gong | Zendy; Jian Li | Zendy; Xiaotian Zhang | Zendy; Jun Zhou | Zendy; Ming Lu | Zendy; Xicheng Wang | Zendy; Zhi Peng | Zendy; Changsong Qi | Zendy; Yanyan Li | Zendy; Jie Li | Zendy; Yan Li | Zendy; Jianyin Zou | Zendy; Xiao Du | Zendy; Henghui Zhang | Zendy; Lin Shen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer

Author(s) -

Zhihao Lü,

Jianling Zou,

Ying Hu,

Shuang Li,

Tao Zhou,

Jifang Gong,

Jian Li,

Xiaotian Zhang,

Jun Zhou,

Ming Lu,

Xicheng Wang,

Zhi Peng,

Changsong Qi,

Yanyan Li,

Jie Li,

Yan Li,

Jianyin Zou,

Xiao Du,

Henghui Zhang,

Lin Shen

Publication year - 2019

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2019.7621

Subject(s) - medicine , cancer , oncology , blockade , gastroenterology , immune checkpoint , immunology , immunotherapy , receptor

Key Points Question Are serological biomarkers associated with response to immune checkpoint blockade in patients with hyperprogressive metastatic gastrointestinal tract cancer? Findings In this cohort study including 56 patients, baseline serum levels of monocyte chemotactic protein 1, leukocyte inhibition factor, and cluster of differentiation 152 were associated with hyperprogressive metastatic gastrointestinal cancer. Early changes in serum interleukin 1 receptor antagonist levels were associated with response to immune checkpoint blockade in patients with metastatic esophageal squamous cell carcinoma and colorectal cancer, and early changes in brain-derived neurotrophic factor levels were associated with response in patients with gastric cancer. Meaning A panel of serological biomarkers may help oncologists identify patients with hyperprogressive disease before immune checkpoint blockade therapy and predict immune checkpoint blockade responses at an early stage, thereby providing an opportunity for early intervention.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research